HER2-positive Gastric Cancer Clinical Trial
Official title:
Disitamab Vedotin Plus Penpulimab and Cisplatin in Advanced Gastric Cancer
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
Although anti-PD-1 antibody could prolong the survival of patients with adanced gastic cancer, there are relatively few reports on anti-PD-1 antibody therapy in Her2-positive gastric cancer. RC48 is a primary anti-HER2 antibody-drug conjugate, which has been approved by the Chinese NMPA for the later-line treatment of Her2-positive gastric cancer. This study was to explore the safety and clinical efficacy of RC48 combined with cisplatin and AK105 in previously untreated patients with HER2-positive gastric cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05070598 -
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03330561 -
PRS-343 in HER2-Positive Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05619016 -
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05586061 -
First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05190445 -
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
|
Phase 2 | |
| Recruiting |
NCT05982834 -
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04520295 -
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
|
||
| Recruiting |
NCT04319757 -
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06253650 -
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
|
Phase 2 | |
| Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
| Recruiting |
NCT06328738 -
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05555251 -
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05514717 -
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
|
Phase 1 | |
| Terminated |
NCT05091528 -
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 | |
| Suspended |
NCT04650451 -
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
|
Phase 1 |